Demyelinating disease and vaccination of the human papillomavirus
Revista de Neurologia (2011)
- PubMed: 21425100
Available from www.ncbi.nlm.nih.gov
or
Abstract
Primary prevention by prophylactic vaccination against the major cause of cervical cancer, the carcinogenic human papillomavirus (HPV) types 16 and 18, is now available worldwide. Postlicensure adverse neurological effects have been described. The studies realized after the license are descriptive and limited by the difficulty to obtain the information, despite most of the statistical indexes show that the adverse effects by the vaccine of the HPV are not upper compared with other vaccines, the substimation must be considered.
Sign up today - FREE
Mendeley saves you time finding and organizing research. Learn more
- All your research in one place
- Add and import papers easily
- Access it anywhere, anytime
Start using Mendeley in seconds!
Readership Statistics
4 Readers on Mendeley
by Discipline
75% Medicine
25% Engineering
by Academic Status
75% Student (Bachelor)
25% Ph.D. Student
by Country
75% Mexico
25% Spain
Groups
 |
|
|
|